Startseite
Kongressberichte 2021
ESMO Congress 2021
Monday, September 20
Mini oral sessions
Melanoma and other skin tumours
Melanoma and other skin tumours
1038MO - Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial
Ivan Marquez-Rodas, et al.
Conclusions
These results are in line with previous data reported for other targeted therapies in this setting, demonstrating a high response rate that is independent of symptomatic status of the pts. Based on this analysis, planned enrollment will continue until completion of accrual.
1039MO - CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)
Kim A., et al.
Conclusions
High concordance was observed between INV- and BICR-assessed responses in this trial for both cohorts. The durable 3-y OS and PFS rates for the asymptomatic cohort support the use of first-line NIVO + IPI. Symptomatic pts with MBM remain difficult to treat, but some can derive long-term benefit from NIVO + IPI.
LBA39 - Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study
Christian U. Blank, et al.
Conclusions
Neoadj NIVO ± DOM ± IPI appears safe and feasible. DONIMI shows prospectively the discriminative ability of the IFN-γ sign algorithm. It adequately identified pts who can benefit from NIVO ± DOM alone (IFN-γ high pts) vs pts who might need an alternative scheme (IFN-γ low pts). Standard DOM dosing (200mg BID d1-14) plus IPI + NIVO is currently being tested.
LBA40 - SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
Paolo A. Ascierto, et al.
Conclusions
The OS and TPFS rates at 2 and 3 years showed a better trend in arm B and C. Data continue to be collected to provide additional information on the long-term benefit of the three treatment combinations. The biomarkers analysis is ongoing.
1041MO - 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma
Reinhard Dummer, et al.
Conclusions
Updated results with enco + bini indicate continued long-term benefit in pts with advanced/metastatic BRAFV600 melanoma.